Registered number: 09811701

INNOVATE LIFE SCIENCES LIMITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

ACQvalue Accountancy

Southbridge House Southbridge Place Croydon Surrey CR0 4HA

Innovate Life Sciences Limited Financial Statements For The Year Ended 31 December 2020

Contents

	Page
Balance Sheet	1
Notes to the Financial Statements	2

Innovate Life Sciences Limited Balance Sheet As at 31 December 2020

Registered number: 09811701

		2020		2019	
	Notes	£	£	£	£
CURRENT ASSETS					
Debtors	4	1,051		445	
Cash at bank and in hand		684		4,281	
		1,735		4,726	
Creditors: Amounts Falling Due Within One Year	5	(9,450)		(9,312)	
NET CURRENT ASSETS (LIABILITIES)		-	(7,715)		(4,586)
TOTAL ASSETS LESS CURRENT LIABILITIES		-	(7,715)		(4,586)
NET LIABILITIES		_	(7,715)		(4,586)
CAPITAL AND RESERVES		-			
Called up share capital	6		10,000		10,000
Share premium account			66,357		66,357
Profit and Loss Account		-	(84,072)		(80,943)
SHAREHOLDERS' FUNDS		=	(7,715)		(4,586)

For the year ending 31 December 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the
 preparation of accounts.
- These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
- The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board		
Mr Christian Fellowes		

Director 16/09/2021

The notes on page 2 form part of these financial statements.

Innovate Life Sciences Limited Notes to the Financial Statements For The Year Ended 31 December 2020

1. Accounting Policies

1.1. Basis of Preparation of Financial Statements

The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Section 1A Small Entities - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

1.2. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract basis by recording turnover and related costs as contract activity progresses.

2. Average Number of Employees

Average number of employees, including directors, during the year was as follows:

	2020	2019
Office and administration	4	4
	4	4
3. Stocks		
	2020	2019
	£	£
4. Debtors		
4. Besters	2020	2019
	£	£
Due within one year		
VAT	1,051	445
	1,051	445
5. Creditors: Amounts Falling Due Within One Year		
	2020	2019
	£	£
Trade creditors	138	-
Directors' loan accounts	9,312	9,312
	9,450	9,312
6. Share Capital		
	2020	2019
Allotted, Called up and fully paid	10,000	10,000

7. General Information

Innovate Life Sciences Limited is a private company, limited by shares, incorporated in England & Wales, registered number 09811701. The registered office is 39 Steeple Close, Poole, Dorset, BH17 9BJ.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic authentication and manner of delivery under section 1072 of the Companies Act 2006.	onic form,